Vicore provides an update on the ATTRACT-3 COVID-19 trial
· ATTRACT-3 did not meet its primary endpoint, reduction of all-cause mortality at 60 days · Lack of effect explained by new virus mutations · No safety signals detected · The company will focus the development of C21 for the treatment of IPF and PAH Gothenburg, September 15, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces the top-line data from the ATTRACT-3 trial in hospitalized COVID-19 patients. In ATTRACT-3[1], a global phase 3 trial,